Justices Experiment With Enablement Paths In Amgen IP Row
The U.S. Supreme Court justices on Monday seemed confused as they grappled for more than an hour and a half over how many antibodies are actually covered by Amgen patents underlying the cholesterol drug Repatha, and how much experimentation it would take to reach the patents' full scope.
The U.S. Supreme Court justices on Monday seemed confused as they grappled for more than an hour and a half over how many antibodies are actually covered by Amgen patents underlying the cholesterol drug Repatha, and how much experimentation it would take to reach the patents' full scope.
What's Your Reaction?
